WO2009089521A3 - Prédicteurs pour évaluer une réponse à une thérapie du cancer - Google Patents

Prédicteurs pour évaluer une réponse à une thérapie du cancer Download PDF

Info

Publication number
WO2009089521A3
WO2009089521A3 PCT/US2009/030719 US2009030719W WO2009089521A3 WO 2009089521 A3 WO2009089521 A3 WO 2009089521A3 US 2009030719 W US2009030719 W US 2009030719W WO 2009089521 A3 WO2009089521 A3 WO 2009089521A3
Authority
WO
WIPO (PCT)
Prior art keywords
predictors
cancer therapy
evaluating response
evaluating
response
Prior art date
Application number
PCT/US2009/030719
Other languages
English (en)
Other versions
WO2009089521A2 (fr
Inventor
W. Fraser Symmans
Christos Hatzis
Lajos Pusztai
Original Assignee
Nuvera Biosciences, Inc.
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvera Biosciences, Inc., The Board Of Regents Of The University Of Texas System filed Critical Nuvera Biosciences, Inc.
Publication of WO2009089521A2 publication Critical patent/WO2009089521A2/fr
Publication of WO2009089521A3 publication Critical patent/WO2009089521A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30—Data warehousing; Computing architectures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Databases & Information Systems (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioethics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés d'évaluation d'un patient et de détermination de la probabilité d'un résultat de traitement par rapport à une ou quatre catégories de classification de charge de cancer résiduelle.
PCT/US2009/030719 2008-01-10 2009-01-12 Prédicteurs pour évaluer une réponse à une thérapie du cancer WO2009089521A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2029208P 2008-01-10 2008-01-10
US61/020,292 2008-01-10

Publications (2)

Publication Number Publication Date
WO2009089521A2 WO2009089521A2 (fr) 2009-07-16
WO2009089521A3 true WO2009089521A3 (fr) 2009-10-08

Family

ID=40853785

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/030719 WO2009089521A2 (fr) 2008-01-10 2009-01-12 Prédicteurs pour évaluer une réponse à une thérapie du cancer

Country Status (1)

Country Link
WO (1) WO2009089521A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201132813A (en) * 2010-03-03 2011-10-01 Koo Foundation Sun Yat Sen Cancer Ct Methods for classifying and treating breast cancers
EP3556870B9 (fr) 2010-07-27 2022-09-28 Genomic Health, Inc. Procédé d'utilisation de l'expression génique pour déterminer le pronostic du cancer de la prostate
WO2013040212A2 (fr) * 2011-09-13 2013-03-21 Baylor Research Institute Signatures transcriptionnelles uniques dans le sang de répondeurs cliniques
CN105917231B (zh) 2014-01-22 2021-05-11 皇家飞利浦有限公司 改进的用于评价疗法适用性的患者分层
KR20230162145A (ko) * 2017-06-23 2023-11-28 아네트 웨이어강 암의 진단 및 치료
CN113943803A (zh) * 2021-10-13 2022-01-18 深圳市人民医院 Htr6在乳腺癌的诊断、预后中的应用
WO2023225327A1 (fr) * 2022-05-19 2023-11-23 The Board Of Regents Of The University Of Texas System Inducteurs de réponse au stress intégrée pour traiter le cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266420A1 (en) * 2004-05-28 2005-12-01 Board Of Regents, The University Of Texas System Multigene predictors of response to chemotherapy
US20060063190A1 (en) * 2004-09-22 2006-03-23 Tripath Imaging, Inc Methods and compositions for evaluating breast cancer prognosis
WO2006119464A1 (fr) * 2005-05-04 2006-11-09 University Of South Florida Prediction de reponse de traitement chez des sujets cancereux
US20070134688A1 (en) * 2005-09-09 2007-06-14 The Board Of Regents Of The University Of Texas System Calculated index of genomic expression of estrogen receptor (er) and er-related genes
KR20070116641A (ko) * 2005-05-11 2007-12-10 에프. 호프만-라 로슈 아게 화학요법에 대한 반응자의 측정

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266420A1 (en) * 2004-05-28 2005-12-01 Board Of Regents, The University Of Texas System Multigene predictors of response to chemotherapy
US20060063190A1 (en) * 2004-09-22 2006-03-23 Tripath Imaging, Inc Methods and compositions for evaluating breast cancer prognosis
WO2006119464A1 (fr) * 2005-05-04 2006-11-09 University Of South Florida Prediction de reponse de traitement chez des sujets cancereux
KR20070116641A (ko) * 2005-05-11 2007-12-10 에프. 호프만-라 로슈 아게 화학요법에 대한 반응자의 측정
US20070134688A1 (en) * 2005-09-09 2007-06-14 The Board Of Regents Of The University Of Texas System Calculated index of genomic expression of estrogen receptor (er) and er-related genes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TESCHENDORFF, A. E. ET AL.: "An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer", GENOME BIOLOGY, vol. 8, no. 8, 2007, pages R157 *

Also Published As

Publication number Publication date
WO2009089521A2 (fr) 2009-07-16

Similar Documents

Publication Publication Date Title
WO2009089521A3 (fr) Prédicteurs pour évaluer une réponse à une thérapie du cancer
EP2046973A4 (fr) Procédés d'identification, d'évaluation, et de traitement de patients soumis à une thérapie anticancéreuse
WO2010083347A3 (fr) Macrocycles peptidomimetiques
HK1211606A1 (en) Identification of tumor-associated antigens for diagnosis and therapy
WO2012054588A3 (fr) Dispositifs à conduits et procédés de détection et de traitement d'analytes
WO2008153705A3 (fr) Procédés de traitement, de diagnostic et de détection de troubles liés à fgf21
WO2010017515A3 (fr) Marqueurs spécifiques du cancer du sein et procédés d’utilisation
MX355543B (es) Macrociclos peptidomiméticos.
EP1994181A4 (fr) Identification et utilisation de novopeptides pour le traitement du cancer
HK1163119A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4
WO2010085542A3 (fr) Biomarqueurs associés à la dégénérescence maculaire liée à l'âge (dmla)
WO2012173846A3 (fr) Macrocycles peptidomimétiques
WO2009009587A3 (fr) Thérapie à base de protéines modulant l'apoptose pour traiter les troubles prolifératifs et nanoparticules les contenant
PL3216457T3 (pl) Związki i sposoby zapobiegania lub leczenia restenozy
WO2009140556A3 (fr) Analyse du génotype et de l'expression permettant de prédire l'évolution d'une maladie et de choisir la thérapie la plus adaptée
WO2010054377A3 (fr) Anticorps entièrement humains dirigés contre la n-cadhérine
WO2010054397A3 (fr) N-cadhérine en tant que cible pour le diagnostic et le traitement du cancer
MY155340A (en) Use of cathepsin c
WO2013164365A3 (fr) Système et procédé prédicteur de modèle de résultat médical d'une dose-réponse
WO2014038682A3 (fr) Méthode de diagnostic et thérapeutique du cancer ciblant des molécules exprimées dans des cellules souches cancéreuses
WO2009074253A3 (fr) Dérivés de phospholipide de clofarabine
WO2010124239A3 (fr) Polymorphismes génétiques associés à des résultats cliniques d'un traitement anticancéreux par des inhibiteurs des topoisomérases
WO2010091296A3 (fr) Emx2 en diagnostic et pronostic du cancer
MY179784A (en) Use of cathepsin h
WO2007013359A3 (fr) Gene rasgef1a associe au cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09700723

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09700723

Country of ref document: EP

Kind code of ref document: A2